Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)

v3.19.3
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Treasure Stock, at cost [Member]
Accumulated Deficit [Member]
Total Emmaus Stockholders' Equity / Deficit [Member]
Non-controlling Interest [Member]
Balance, beginning at Dec. 31, 2017 $ 14,291 $ 37 $ 113,110 $ 41,276   $ (140,132) $ 14,291  
Balance, beginning (in shares) at Dec. 31, 2017   36,634,856            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Cumulative effect adjustment on adoption | ASU 2016-01 [Member]       (41,362)   41,362    
Beneficial conversion feature relating to convertible notes payable 3,638   3,638       3,638  
Common stock issued for cash (net of issuance cost) 275   275       275  
Common stock issued for cash (net of issuance cost) (in shares)   26,254            
Repurchase of stock (1,314)       $ (1,314)   (1,314)  
Share-based compensation 710   710       710  
Foreign currency translation effect 14     14     14  
Net income (loss) (6,097)         (6,097) (6,097)  
Balance, ending at Mar. 31, 2018 11,517 $ 37 117,733 (72) (1,314) (104,867) 11,517  
Balance, ending (in shares) at Mar. 31, 2018   36,661,110            
Balance, beginning at Dec. 31, 2017 14,291 $ 37 113,110 41,276   (140,132) 14,291  
Balance, beginning (in shares) at Dec. 31, 2017   36,634,856            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Foreign currency translation effect 11              
Net income (loss) (38,873)              
Balance, ending at Sep. 30, 2018 (11,544) $ 38 126,136 (75)   (137,643) (11,544)  
Balance, ending (in shares) at Sep. 30, 2018   37,755,675            
Balance, beginning at Dec. 31, 2017 14,291 $ 37 113,110 41,276   (140,132) 14,291  
Balance, beginning (in shares) at Dec. 31, 2017   36,634,856            
Balance, ending at Dec. 31, 2018 (15,894) $ 37 140,903 (69)   (156,668) (15,797) $ (97)
Balance, ending (in shares) at Dec. 31, 2018   37,341,393            
Balance, beginning at Mar. 31, 2018 11,517 $ 37 117,733 (72) (1,314) (104,867) 11,517  
Balance, beginning (in shares) at Mar. 31, 2018   36,661,110            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beneficial conversion feature relating to convertible notes payable 5,583   5,583       5,583  
Repurchase of stock   $ (1) 1          
Repurchase of stock (in shares)   (735,102)            
Share-based compensation 955   955       955  
Exercise of warrants (cashless) (in shares)   8,733            
Foreign currency translation effect 2     2     2  
Net income (loss) (47,345)         (47,345) (47,345)  
Balance, ending at Jun. 30, 2018 (29,288) $ 36 124,272 (70) (1,314) (152,212) (29,288)  
Balance, ending (in shares) at Jun. 30, 2018   35,934,741            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beneficial conversion feature relating to convertible notes payable 997   997       997  
Exercise of warrants 105   105       105  
Exercise of warrants (in Shares)   31,504            
Cancellation of stock     (1,314)   $ 1,314      
Share-based compensation 2,078   2,078       2,078  
Exercise of stock option (cashless)   $ 1 (1)          
Exercise of stock option (cashless) (in shares)   88,473            
Exercise of warrants (cashless)   $ 1 (1)          
Exercise of warrants (cashless) (in shares)   1,700,957            
Foreign currency translation effect (5)     (5)     (5)  
Net income (loss) 14,569         14,569 14,569  
Balance, ending at Sep. 30, 2018 (11,544) $ 38 126,136 (75)   (137,643) (11,544)  
Balance, ending (in shares) at Sep. 30, 2018   37,755,675            
Balance, beginning at Dec. 31, 2018 (15,894) $ 37 140,903 (69)   (156,668) (15,797) (97)
Balance, beginning (in shares) at Dec. 31, 2018   37,341,393            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Cumulative effect adjustment on adoption | ASC 842 [Member] (29)         (29) (29)  
Beneficial conversion feature relating to convertible notes payable 2,039   2,039       2,039  
Exercise of warrants 5   5       5  
Exercise of warrants (in Shares)   525            
Common stock issued for cash (net of issuance cost) 2,530   2,530       2,530  
Common stock issued for cash (net of issuance cost) (in shares)   322,920            
Conversion of convertible notes payable and notes payable to common stock 329   329       329  
Conversion of convertible notes payable and notes payable to common stock (in shares)   85,410            
Share-based compensation 536   536       536  
Exercise of stock options 1   1       1  
Exercise of stock options (in shares)   175            
Foreign currency translation effect 8     7     7 1
Net income (loss) (14,153)         (14,167) (14,167) 14
Balance, ending at Mar. 31, 2019 (24,628) $ 37 146,343 (62)   (170,864) (24,546) (82)
Balance, ending (in shares) at Mar. 31, 2019   37,750,423            
Balance, beginning at Dec. 31, 2018 (15,894) $ 37 140,903 (69)   (156,668) (15,797) (97)
Balance, beginning (in shares) at Dec. 31, 2018   37,341,393            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Cumulative effect adjustment on adoption | ASU 2016-01 [Member] 41,400              
Foreign currency translation effect 10              
Net income (loss) (59,563)              
Balance, ending at Sep. 30, 2019 (18,250) $ 47 199,395 (51)   (216,916) (17,525) (725)
Balance, ending (in shares) at Sep. 30, 2019   47,671,446            
Balance, beginning at Mar. 31, 2019 (24,628) $ 37 146,343 (62)   (170,864) (24,546) (82)
Balance, beginning (in shares) at Mar. 31, 2019   37,750,423            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Beneficial conversion feature relating to convertible notes payable 5,391   5,391       5,391  
Exercise of warrants 181   181       181  
Exercise of warrants (in Shares)   53,032            
Common stock issued for cash (net of issuance cost) 730   730       730  
Common stock issued for cash (net of issuance cost) (in shares)   76,755            
Share-based compensation 438   438       438  
Foreign currency translation effect (9)     6     6 (15)
Net income (loss) (19,327)         (18,639) (18,639) (688)
Balance, ending at Jun. 30, 2019 (37,224) $ 37 153,083 (56)   (189,503) (36,439) (785)
Balance, ending (in shares) at Jun. 30, 2019   37,880,210            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Common stock issued for cash (net of issuance cost) 2,950 $ 1 2,949       2,950  
Common stock issued for cash (net of issuance cost) (in shares)   477,338            
Conversion of convertible notes payable and notes payable to common stock 35,509 $ 7 35,502       35,509  
Conversion of convertible notes payable and notes payable to common stock (in shares)   6,983,350            
Notes conversion expense 3,906   3,906       3,906  
Reclassification of warrant liability to equity 776   776       776  
Common stock issued in merger (1,642) $ 2 (1,644)       (1,642)  
Common stock issued in merger ( in shares)   2,330,548            
Share-based compensation 129   129       129  
Fair value of replacement equity awards 2,438   2,438       2,438  
Fair value of placement agent warrant including down-round protection adjustments 980   2,256     (1,276) 980  
Foreign currency translation effect 11     5     5 6
Net income (loss) (26,083)         (26,137) (26,137) 54
Balance, ending at Sep. 30, 2019 $ (18,250) $ 47 $ 199,395 $ (51)   $ (216,916) $ (17,525) $ (725)
Balance, ending (in shares) at Sep. 30, 2019   47,671,446